Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year High – Should You Buy?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares reached a new 52-week high on Friday . The company traded as high as $21.16 and last traded at $21.16, with a volume of 9412874 shares changing hands. The stock had previously closed at $12.78.

Trending Headlines about Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

Analysts Set New Price Targets

Several equities analysts recently commented on DAWN shares. Wedbush downgraded shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday. TD Cowen downgraded shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Friday. HC Wainwright reduced their price objective on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Finally, Zacks Research cut Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $25.56.

Day One Biopharmaceuticals Trading Up 65.9%

The firm has a market capitalization of $2.19 billion, a P/E ratio of -20.58 and a beta of -1.25. The company has a 50-day moving average of $11.10 and a 200-day moving average of $9.06.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). The company had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. Research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insiders Place Their Bets

In related news, insider Lauren Merendino sold 5,814 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $67,442.40. Following the sale, the insider directly owned 60,157 shares in the company, valued at $697,821.20. This represents a 8.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Charles N. York II sold 6,065 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $70,354.00. Following the transaction, the chief financial officer owned 312,025 shares of the company’s stock, valued at approximately $3,619,490. The trade was a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 36,461 shares of company stock valued at $422,948 over the last three months. Insiders own 6.20% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently bought and sold shares of DAWN. Federated Hermes Inc. bought a new stake in Day One Biopharmaceuticals during the third quarter valued at $39,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after purchasing an additional 1,029 shares during the period. Ameritas Investment Partners Inc. lifted its stake in shares of Day One Biopharmaceuticals by 44.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after purchasing an additional 2,264 shares during the period. Quarry LP bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $49,000. Finally, Entropy Technologies LP acquired a new stake in Day One Biopharmaceuticals during the second quarter worth approximately $67,000. Institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.